Suppr超能文献

骨转换、矿化及体积的组织形态计量学测量

Histomorphometric measurements of bone turnover, mineralization, and volume.

作者信息

Ott Susan M

机构信息

Department of Medicine, University of Washington, Seattle, WA 98195-6426, USA.

出版信息

Clin J Am Soc Nephrol. 2008 Nov;3 Suppl 3(Suppl 3):S151-6. doi: 10.2215/CJN.04301206.

Abstract

A recent Kidney Disease: Improving Global Outcomes report suggested that bone biopsies in patients with chronic kidney disease should be characterized by determining bone turnover, mineralization, and volume. This article focuses on the calculations and interpretation of these measurements. In most cases of renal osteodystrophy, the bone formation rate is roughly similar to the bone resorption rate; therefore, the bone formation indices can be used to describe turnover. It is important to remember that these conventions will not apply in some situations. Activation frequency should not be confused with bone formation rate or bone metabolic unit birth rate. Abnormal mineralization can be described using the osteoid volume, increased osteoid maturation time, or increased mineralization lag time. The concept of bone volume is the easiest to understand, but there is a large error from one biopsy to the next in the same person. There are some difficulties with each of the measurements, and further research in patients with chronic kidney must be done to enable a consensus to be reached about cut points to define categories within the spectrum of renal osteodystrophy and how to evaluate treatment responses.

摘要

近期发布的一份《改善全球肾脏病预后》报告建议,慢性肾脏病患者的骨活检应通过测定骨转换、矿化和骨量来进行特征描述。本文重点关注这些测量指标的计算与解读。在大多数肾性骨营养不良病例中,骨形成速率与骨吸收速率大致相似;因此,骨形成指标可用于描述骨转换。需要牢记的是,这些惯例在某些情况下并不适用。激活频率不应与骨形成速率或骨代谢单位生成速率相混淆。异常矿化可用类骨质体积增加、类骨质成熟时间延长或矿化延迟时间延长来描述。骨量的概念最容易理解,但同一人每次活检之间的误差较大。每项测量都存在一些困难,必须对慢性肾脏病患者开展进一步研究,以便就肾性骨营养不良范围内定义分类的切点以及如何评估治疗反应达成共识。

相似文献

1
Histomorphometric measurements of bone turnover, mineralization, and volume.
Clin J Am Soc Nephrol. 2008 Nov;3 Suppl 3(Suppl 3):S151-6. doi: 10.2215/CJN.04301206.
3
Micro-CT in the Assessment of Pediatric Renal Osteodystrophy by Bone Histomorphometry.
Clin J Am Soc Nephrol. 2016 Mar 7;11(3):481-7. doi: 10.2215/CJN.04810515. Epub 2015 Dec 28.
4
Bone histomorphometry in renal osteodystrophy.
Semin Nephrol. 2009 Mar;29(2):122-32. doi: 10.1016/j.semnephrol.2009.01.005.
5
Update on the role of bone biopsy in the management of patients with CKD-MBD.
J Nephrol. 2017 Oct;30(5):645-652. doi: 10.1007/s40620-017-0424-8. Epub 2017 Aug 22.
8
Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry.
Curr Opin Nephrol Hypertens. 2003 Jul;12(4):387-403. doi: 10.1097/00041552-200307000-00007.
9
Bone health in chronic kidney disease-mineral and bone disease.
Adv Chronic Kidney Dis. 2007 Jan;14(1):27-36. doi: 10.1053/j.ackd.2006.10.010.
10
Effects of treatment of renal osteodystrophy on bone histology.
Clin J Am Soc Nephrol. 2008 Nov;3 Suppl 3(Suppl 3):S157-63. doi: 10.2215/CJN.02500607.

引用本文的文献

2
Evaluation of Bone Biomarkers in Renal Osteodystrophy.
Life (Basel). 2024 Nov 25;14(12):1540. doi: 10.3390/life14121540.
3
Precision Renal Osteodystrophy: What's Race Got to do With It?
Curr Osteoporos Rep. 2024 Dec 2;23(1):5. doi: 10.1007/s11914-024-00894-y.
4
The transcription factor BBX regulates phosphate homeostasis through the modulation of FGF23.
Exp Mol Med. 2024 Nov;56(11):2436-2448. doi: 10.1038/s12276-024-01341-9. Epub 2024 Nov 1.
5
Between a Rock and a Short Place-The Impact of Nephrolithiasis on Skeletal Growth and Development Across the Lifespan.
Curr Osteoporos Rep. 2024 Dec;22(6):576-589. doi: 10.1007/s11914-024-00888-w. Epub 2024 Oct 2.
6
Splicing factor YBX1 regulates bone marrow stromal cell fate during aging.
EMBO J. 2023 May 2;42(9):e111762. doi: 10.15252/embj.2022111762. Epub 2023 Mar 21.
7
Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease.
Pharmaceuticals (Basel). 2022 Jul 31;15(8):952. doi: 10.3390/ph15080952.
8
Use of Eggshells as Bone Grafts around Commercially Pure Titanium Implant Screws Coated with Nano Calcium Sulfate.
Int J Biomater. 2022 Aug 10;2022:8722283. doi: 10.1155/2022/8722283. eCollection 2022.
9
Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease.
Front Pharmacol. 2021 Dec 21;12:785375. doi: 10.3389/fphar.2021.785375. eCollection 2021.

本文引用的文献

1
Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis.
Am J Kidney Dis. 2007 May;49(5):674-81. doi: 10.1053/j.ajkd.2007.02.264.
2
Development of renal bone disease.
Eur J Clin Invest. 2006 Aug;36 Suppl 2:2-12. doi: 10.1111/j.1365-2362.2006.01661.x.
4
Effect of testosterone replacement on trabecular architecture in hypogonadal men.
J Bone Miner Res. 2005 Oct;20(10):1785-91. doi: 10.1359/JBMR.050606. Epub 2005 Jun 20.
6
Osteoporosis in chronic kidney disease.
Am J Kidney Dis. 2004 Mar;43(3):566-71. doi: 10.1053/j.ajkd.2003.12.004.
7
Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy.
Am J Kidney Dis. 2004 Mar;43(3):558-65. doi: 10.1053/j.ajkd.2003.12.003.
8
Pathophysiology and recent advances in the management of renal osteodystrophy.
J Bone Miner Res. 2002 Dec;17(12):2094-105. doi: 10.1359/jbmr.2002.17.12.2094.
10
Mineralized bone loss at different sites in dialysis patients: implications for prevention.
J Am Soc Nephrol. 1998 Jul;9(7):1225-33. doi: 10.1681/ASN.V971225.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验